Floatz logo

Ceftobiprole

Streptococcal Infections

Basilea PharmaceuticaSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Streptococcal Infections cohort.

Asset / SponsorPhaseRating
POLIO SABIN
GlaxoSmithKline
Phase 3BB
Tritanrix-HepB
GlaxoSmithKline
Phase 3BB
gsk1024850a
GlaxoSmithKline
Phase 3BB
H INFLUENZAE B WHOLE
GlaxoSmithKline
Phase 3BB
Oritavancin
Targanta Therapeutics Corporation
Phase 2B

Same molecule, other indications

Ceftobiprole is also rated in:

staphylococcal infectionDormant
CC
Indicative ·
47 / 100
View asset →
obesity disorderDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →